RT Journal Article
SR Electronic
T1 C-reactive protein guided use of procalcitonin in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.10.21251350
DO 10.1101/2021.02.10.21251350
A1 Rebecca Houghton
A1 Nathan Moore
A1 Rebecca Williams
A1 Fatima El-Bakri
A1 Jonathan Peters
A1 Matilde Mori
A1 Gabrielle Vernet
A1 Jessica Lynch
A1 Henry Lewis
A1 Maryanna Tavener
A1 Tom Durham
A1 Jack Bowyer
A1 Kordo Saeed
A1 Gabriele Pollara
YR 2021
UL http://medrxiv.org/content/early/2021/02/12/2021.02.10.21251350.abstract
AB Low procalcitonin (PCT) concentrations (<0.5ng/mL) can facilitate exclusion of bacterial co-infection in viral infections, including COVID-19. However, costs associated with PCT measurement preclude universal adoption, indicating a need to identify settings where PCT provides clinical information beyond that offered by other inflammatory markers, such as C-reactive protein (CRP) and white cell count (WCC). In an unselected cohort of 299 COVID-19 patients, we tested the hypothesis that PCT<0.5ng/mL was associated with lower levels of CRP and WCC. We demonstrated that CRP values below the geometric mean of the entire patient population had a negative predictive value for PCT<0.5ng/mL of 97.6% and 100% at baseline and 48 hours into admission respectively, and that this relationship was not confounded by intensive care admission or microbiological findings. CRP-guided PCT testing algorithms can reduce costs and support antimicrobial stewardship strategies in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received to undertake the work presented.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Research and Development department at Hampshire Hospitals NHS Trust, which in its capacity as IRB, stated that as this was a retrospective review of routine clinical data, formal ethics approval was not required, and that confidential patient information could be used under the COVID-19 COPI notice issued by the UK Department of Health and Social Care.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll anonymised data presented in the manuscript is available to others by request of the corresponding author.